A comprehensive view of European Medicines Agency. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Janssen Submits Type II Extension of Indication Application to the European Medicines Agency Seeking Approval of RYBREVANT®▼ (amivantamab), in combination with Lazertinib, for First-Line Treatment of ...

European regulators accept GSK's application to expand use of its adjuvanted recombinant RSV vaccine Arexvy to adults aged 50-59 at increased risk of disease; product is currently approved in adults aged 60 and older

European Medicines Agency Validates Type II Variation Application for PADCEV® (enfortumab vedotin) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer

European Medicines Agency validates Bristol Myers Squibb's marketing authorization application for repotrectinib; the drug is a potential treatment for ROS1-positive non-small cell lung cancer and NTRK-positive solid tumors

Janssen submits marketing authorisation application to the European Medicines Agency seeking approval of Lazertinib, in combination with RYBREVANT amivantamab, for the first-line treatment of patients with EGFR-mutated non-small cell lung cancer

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count